SCHEMBL6722950

SCHEMBL6722950

CC(C)(C)C(C)(C)C#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL576290 0.82 ALDH1A1 (0.36)
SCHEMBL25996661 0.77
Methyl Alcohol SCHEMBL27971014 0.75 TDP1 (0.35)
SCHEMBL1057067 0.69
SCHEMBL20332783 0.69
SCHEMBL13174216 0.69
SCHEMBL27426085 0.69
SCHEMBL10615083 0.69
SCHEMBL26762914 0.69
SCHEMBL5719204 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4565207-A1 CORE-SHELL CAPSULES AND USES THEREOF President And Fellows Of Harvard College (US) 2025-06-11 EP disclosed
US-20240208981-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-27 US disclosed
WO-2024030526-A1 CORE-SHELL CAPSULES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-02-08 WO disclosed
US-20230365525-A1 ANTIVIRAL COMPOUNDS ENANTA PHARMACEUTICALS, INC. 2023-11-16 US disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20230157293-A1 NAPHTHALENE ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS FMC CORPORATION 2023-05-25 US disclosed
US-8703759-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2014-04-22 US disclosed
US-8182975-B2 Positive resist composition and pattern forming method using the same FUJIFILM CORPORATION (JP) 2012-05-22 US disclosed
US-20120010192-A1 Fused Heterocyclic Compounds as Ion Channel Modulators GILEAD SCIENCES, INC. 2012-01-12 US disclosed
US-8012909-B2 Receiver sheet includes receptor layer containing yellow, cyan, magenta dyes; superimposing heat sensitive transfer sheet ; heating; process control FUJIFILM CORPORATION (JP) 2011-09-06 US disclosed
US-20110021521-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2011-01-27 US disclosed
US-20080248419-A1 POSITIVE RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME FUJIFILM CORPORATION (JP) 2008-10-09 US disclosed
US-4721591-A Method for the preparation of cross-linked polyethylene foams and foams produced by the method DOW CHEMICAL IBERICA S.A. (ES) 1988-01-26 US disclosed
EP-0210760-A2 Method for the preparation of cross-linked polyethylene foams and foams produced by the method BP CHEMICALS FOAMS BUSINESS, SA (ES) 1987-02-04 EP disclosed
US-4200720-A HYDROXIDE OR NUCLEOPHILIC SALT OF A MONOVALENT CATION THE DOW CHEMICAL COMPANY (US) 1980-04-29 US disclosed
US-4180637-A Process for the preparation of low molecular weight anhydride interpolymers THE DOW CHEMICAL COMPANY (US) 1979-12-25 US disclosed